Abstract
Introduction T cell lymphomas contribute to less than 15 percent of Non-Hodgkin lymphoma in adults. Peripheral T cell lymphoma, not otherwise specified (PTCL, NOS), Anaplastic large cell lymphoma (ALCL), Angioimmunoblastic T cell lymphoma (AITL) contribute to approximately 75 percent of these T cell lymphomas. We did a population based study to evaluate the role of stem cell transplant and immunotherapy on survival outcome in stage four T cell lymphoma. Methods Data was analyzed from 4395 men and women (≥ 18 years of age) registered in the National Cancer Database (NCDB) who were diagnosed with stage four T cell lymphoma – PTCL, ALCL and AITL between 2004 and 2013 and had follow-ups to end of 2014. The primary predictor variable was treatment received, and overall survival was the outcome variable. Additional variables addressed and adjusted included gender, age, race, Charleston Comorbidity Index and histology. Results The mean age of patients was 58 years with standard deviation of 16. In multivariate analysis, after adjusting for secondary predictor variables, treatment modality was a statistically significant predictor of overall survival. Chemotherapy, SCT and immunotherapy decreased the mortality risk by 52, 70 and 22 %, respectively. Among the group with immunotherapy, pts with PTCL NOS and AITCL ALK negative derived the greatest benefit. Conclusion SCT and immunotherapy leads to improved survival in pts with T cell lymphoma. Among pts with T cell lymphoma, PTCL and ALCL ALK -, derive the greatest benefit from immunotherapy. Further clinical; research needs to be done to evaluate the role of immunotherapy in T cell lymphoma
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
